Amicus Therapeutics (FOLD) News Today → Secret energy grid to power millions of homes (From Porter & Company) (Ad) Free FOLD Stock Alerts $10.05 -0.22 (-2.14%) (As of 06/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 8 at 7:16 PM | marketbeat.comSeven Eight Capital LP Has $2 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Seven Eight Capital LP grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 313.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 140,581 shares of theJune 7 at 1:26 AM | americanbankingnews.comBrokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.57June 6 at 4:44 AM | marketbeat.comWells Fargo & Company MN Trims Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wells Fargo & Company MN lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 570,956 shares of the biopharmaceutiJune 5 at 1:06 PM | globenewswire.comIn NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private FundsJune 5 at 8:32 AM | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Rafferty Asset Management LLCRafferty Asset Management LLC lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 795,351 shares of the biopJune 5 at 7:00 AM | globenewswire.comAmicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 4, 2024 | marketbeat.comCampbell & CO Investment Adviser LLC Has $2.42 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Campbell & CO Investment Adviser LLC grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 1,447.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 170,431 shares of the biopharmaceutical company's stock after purchJune 4, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buyJune 4, 2024 | americanbankingnews.comAmicus Therapeutics, Inc. Expected to Post Q3 2025 Earnings of $0.05 Per Share (NASDAQ:FOLD)June 3, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Forecasted to Earn Q3 2025 Earnings of $0.05 Per ShareAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities researchers at Zacks Research cut their Q3 2025 EPS estimates for Amicus Therapeutics in a research note issued to investors on Thursday, May 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical compJune 2, 2024 | marketbeat.comUBS Group AG Acquires 303,038 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)UBS Group AG boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 58.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 824,708 shares of the biopharmaceutical company's stock after purchaJune 1, 2024 | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.36May 31, 2024 | marketbeat.comNorges Bank Acquires New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Norges Bank acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 2,531,000 shares of the biopharmaceutical company's stock, valued at approximatelyMay 30, 2024 | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Analysts at Wells Fargo & CompanyMay 24, 2024 | msn.comDo Options Traders Know Something About Amicus (FOLD) Stock We Don't?May 22, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,268,886 shares of the biopharmaceutical company's stocMay 20, 2024 | seekingalpha.comAmicus Therapeutics: Too Cheap At Under $10 A ShareMay 18, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Massachusetts Financial Services Co. MA increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,415,090May 16, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 138.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 923,045 shares of the biopharmaceutical company's stock after purchasing an additionMay 15, 2024 | marketbeat.comM&G Investment Management Ltd. Takes $9.95 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)M&G Investment Management Ltd. acquired a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 710,557 shares of the biopharmMay 14, 2024 | msn.comGuggenheim Upgrades Amicus Therapeutics (FOLD)May 14, 2024 | markets.businessinsider.comEvaluating Amicus Therapeutics: Insights From 6 Financial AnalystsMay 14, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $9.04May 14, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded by Guggenheim to "Buy"Guggenheim upgraded Amicus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a report on Tuesday.May 10, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Issues Earnings ResultsAmicus Therapeutics (NASDAQ:FOLD - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. The business had revenue of $110.40 million during the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Amicus Therapeutics's quarterly revenue was up 27.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) earnings per share.May 10, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) PT Lowered to $19.00 at UBS GroupUBS Group cut their target price on Amicus Therapeutics from $20.00 to $19.00 and set a "buy" rating for the company in a research report on Friday.May 10, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...May 10, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Friday.May 10, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Rating of "Buy" from BrokeragesAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned an average recommendation of "Buy" from the three research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a buy rating. The average twelve-monthMay 9, 2024 | investorplace.comFOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week Low at $9.30Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year Low at $9.30May 9, 2024 | washingtonpost.comAmicus Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAmicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate UpdatesMay 9, 2024 | marketbeat.comVictory Capital Management Inc. Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Victory Capital Management Inc. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,687 shMay 8, 2024 | globenewswire.comAmicus Therapeutics to Present at the Bank of America 2024 Health Care ConferenceMay 8, 2024 | barrons.comAmicus Therapeutics Inc.May 4, 2024 | insidertrades.comInsider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 7,500 Shares of StockMay 2, 2024 | marketbeat.comAmicus Therapeutics (FOLD) to Release Quarterly Earnings on ThursdayAmicus Therapeutics (NASDAQ:FOLD) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 1, 2024 | globenewswire.comAmicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024April 21, 2024 | marketbeat.comVontobel Holding Ltd. Purchases New Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Vontobel Holding Ltd. purchased a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 82,672 shares of the biopharmaceutical company's stock, valued at approximately $1,173,000.April 14, 2024 | nasdaq.comAmicus Therapeutics Becomes Oversold (FOLD)April 10, 2024 | marketbeat.comPeregrine Capital Management LLC Reduces Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Peregrine Capital Management LLC reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 16.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 605,348 shares of the biopharmaceutical company'sMarch 30, 2024 | msn.comNevada’s Lee joins on to Amicus Brief in SCOTUS abortion caseMarch 29, 2024 | msn.comNevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion caseMarch 28, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5%Amicus Therapeutics (NASDAQ:FOLD) Trading Down 2.5%March 27, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,131,873 shares of the biopharmaceuticalMarch 22, 2024 | marketbeat.comZacks Research Comments on Amicus Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:FOLD)Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Zacks Research boosted their Q1 2024 earnings per share estimates for Amicus Therapeutics in a report released on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earningsMarch 21, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q3 2024 Earnings of $0.01 Per Share, Zacks Research ForecastsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Stock analysts at Zacks Research issued their Q3 2024 EPS estimates for shares of Amicus Therapeutics in a research report issued on Wednesday, March 20th. Zacks Research analyst R. Department expects that the biopharmaceutical company willMarch 20, 2024 | marketbeat.comAmicus Therapeutics Target of Unusually High Options Trading (NASDAQ:FOLD)Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) saw some unusual options trading on Wednesday. Stock traders acquired 10,103 call options on the company. This is an increase of approximately 1,275% compared to the typical volume of 735 call options. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking - The US Gov. Seized CITGO (Ad)Do you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd). Get all the details here. FOLD Media Mentions By Week FOLD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.610.73▲Average Medical News Sentiment FOLD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼144▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BHVN News ARWR News BHC News PRGO News BBIO News ALLK News BPMC News RGEN News EXAS News EXEL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored